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journal homepage: www.journal-surgery.netEditorialEndocrine surgery: Current and future issuesEndocrine surgery represents a challenging ﬁeld of uses, rich of
pathophysiologic consequences, subject of never-ending research
and controversies. During the last twenty years brilliant improve-
ments in technology, in the mininvasive techniques and in the peri-
operative support have allowed the short-lasting low-morbidity
resolution of diseases of thyroid, parathyroid, pancreas and adrenal
glands.
Genetics has proved to be of great help for familial screening,
and for leading, by targeting genomic mutations, “preventive” sur-
gery, such as in the medullary thyroid carcinoma. Also, molecular
biology has showed with a remarkable accuracy the cell-based
pathogenesis, and has identiﬁed markers of great clinical and prog-
nostic value.
Beyond any doubt, the development of diagnostic imaging has
allowed the recognition of subcentimetric neoplasms with an
incredible precision, and as a consequence detection studies have
replaced diagnostic laparotomies.
The best knowledge of regulatory mechanisms in the hormonal
activity and in the relationships between endocrine glands and
their related target, and an unlimited incitement for the research
has produced a reasonable and evidence-based proposal of new
diagnostic therapeutic paths for the patients suffering from endo-
crine diseases. The employment of shared international protocols
represents the real next challenge, which will enable a homoge-
neous analysis of the therapeutic results.
Healing, a best quality of life following surgery, rationalization of
approaches and cost-effective policies remain the undisputed ob-
jectives of a target-aimed clinical research.
Regarding thyroid gland, a better preoperative assessment of
suspicious lesions is still a scope of great interest, such as, in the
treatment of differentiated carcinoma, lymphectomies and radioa-
blative therapy are subject of discussions. Mininvasive surgery,
sometimes suggested by means of more elaborated accesses, has
showed results comparable to the ones achieved by surgeons in a
classical approach. In this ﬁeld, the value of robotics must be
conﬁrmed also by costs.
Indications to parathyroidectomy for primary HPT are still sub-
ject of debates across guidelines, while detection studies have
conclusively allowed less invasive approaches for an ambulatory
surgery. The diffusion of calcimimetics has revolutionized therapies
of the secondary forms, but a comparison among long-term results
between drugs and surgery is still subject of research, also in terms
of costs.
It is also sure that mininvasive approach of adrenal glands is
already a “gold-standard”, also for pheochromocytomas and some
metastatic forms, while the one-trocar retroperitoneal technique
seems to be a next-coming approach. The right indications to the
treatment of incidental lesions are subject of debating, such ashttp://dx.doi.org/10.1016/j.ijsu.2014.05.075
1743-9191/© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.the role of the “sparing adrenalectomy”, mainly in the treatment
of the bilateral disease, where it needs perspective randomized
trials.
Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
appear to be a clinical challenge, showing a high incidence (because
of missed diagnoses in the past time) and a signiﬁcant possibility of
cure. In this area, immunohistochemical studies, and overall instru-
mental diagnoses, has reported surprising improvements. Biolog-
ical drugs represent a real therapeutic innovation, and they are
strictly tied to the hope of improving the results, still inadequate,
of some rare aggressive forms.
Targeted therapies in a multidisciplinary environment still
represent a challenge for the future.
In brief, endocrine surgery of the twenty-ﬁrst century has to be
intended as a tile in the wide mosaic of approaches to the diseases,
where only a strict partnership among researchers, endocrinolo-
gists, radiologists, oncologists and surgeons, in referral units, can
produce the best therapeutic outcomes.
The Italian Society of Endocrine Surgery is one of the most
ancient and famous surgical societies in our country, and its next
Spring Meeting will be held in Naples on the 26th and 27th of
May 2014. Differentiated thyroid carcinomas, hyperparathyroidism,
adrenal diseases, pancreatic neuroendocrine tumors, breast cancer
and obesity surgery will be the main topics, with over one hundred
lecturers from all the Italian regions.
During these two days, the meeting, accredited by the Ministry
of Health, will be divided into two preceding workshops and seven
scientiﬁc sessions of relevant interest.
A special prize will be awarded by a special jury of national ex-
perts led by a President to a young surgeon (“under 40”) for the best
oral presentation of an endocrine clinical case of special interest.
We hope that a certain contribution to the advancement of the
most recent knowledge in endocrine surgery, especially in terms of
technological innovation, will be achieved.
Welcome to the Congress,
Luigi Santini and Giovanni Conzo.
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